Cargando…
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
OBJECTIVE: To investigate in real-life the conversion from chronic migraine (CM) to episodic migraine (EM), specifically to EM with High-Frequency (HFEM: 8–14 monthly migraine days, MMDs), Medium-Frequency (MFEM, 4–7 MMDs), and Low-Frequency EM (LFEM, 0–3 MMDs), and its persistence during 1 year of...
Autores principales: | Altamura, Claudia, Brunelli, Nicoletta, Marcosano, Marilena, Aurilia, Cinzia, Egeo, Gabriella, Lovati, Carlo, Favoni, Valentina, Perrotta, Armando, Maestrini, Ilaria, Schiano Di Cola, Francesca, d’Onofrio, Florindo, Finocchi, Cinzia, Bertuzzo, Davide, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Messina, Roberta, Doretti, Alberto, Di Piero, Vittorio, Cevoli, Sabina, Barbanti, Piero, Vernieri, Fabrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243974/ https://www.ncbi.nlm.nih.gov/pubmed/35763113 http://dx.doi.org/10.1007/s00415-022-11226-4 |
Ejemplares similares
-
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022) -
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021) -
Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022) -
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
por: Altamura, Claudia, et al.
Publicado: (2020) -
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)